Ergebnisse einschränken

p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-α and melphalan

Muret, J. ; Yacoub, M. ; Terrier, P. ; Drusch, F. ; Laplanche, A. ; Gaudin, C. ; Richon, C. ; Le Péchoux, C. ; Le Cesne, A. ; Lejeune, F. J. ; Tursz, T. ; Fouret, P. ; Bonvalot, S. ; Chouaib, S.

In: Annals of Oncology, 2007, vol. 19, no. 4, p. 793-800

Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation

Buser, K. ; Bacchi, M. ; Goldhirsch, A. ; Greiner, R. ; Diener, P. ; Sessa, C. ; Jungi, W. F. ; Forni, M. ; Leyvraz, S. ; Engeler, V.

In: Annals of Oncology, 1996, vol. 7, no. 1, p. 65-70

The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model

Hagen, Timo L.M. ten ; Seynhaeve, Ann L.B. ; Wiel-Ambagtsheer, Gisela aan de ; Bruijn, Ernst A. de ; Tiel, Sandra T. van ; Rüegg, Curzio ; Meyring, Michael ; Grell, Matthias ; Goodman, Simon L. ; Eggermont, Alexander M.M.

In: International Journal of Cancer, 2012, p. -

Isolated limb perfusion (ILP) with melphalan and tumor necrosis factor (TNF)-α is used to treat bulky, locally advanced melanoma and sarcoma. However, TNF toxicity suggests a need for better-tolerated drugs. Cilengitide (EMD 121974), a novel cyclic inhibitor of alpha-V integrins, has both anti-angiogenic and direct anti-tumor effects and is a possible alternative to TNF in ILP. In this study,...